AstraZeneca Hopes To Differentiate Benralizumab On Efficacy, Dosing Convenience
This article was originally published in The Pink Sheet Daily
Executive Summary
Biologic for severe asthma meets primary endpoint in two pivotal studies, but greater detail will be needed to differentiate the drug from already-approved Nucala and Cinqair.